Table 1.
Patient characteristics of all patients (n=51). Data presented as number of patients (percentage) for non-continuous variables and as median (IQR) for continuous parameters.
| All patients (n=51) | |
|---|---|
| Sex n (Male/Female) | 23/28 |
| Diagnosis of liver disease | |
| Biliary atresia n (%) | 19 (34) |
| Metabolic disease* n (%) | 8 (16) |
| Hepatitis n(%) | 7 (14) |
| Hepatic malignancy n (%) | 5 (10) |
| PKD/congenital fibrosis n (%) | 4 (8) |
| Other** n (%) | 8 (14) |
| Surgical characteristics | |
| Age at LT (years) | 3.3 (1.3–13.6) |
| Time from LT to first follow-up (years) | 11.3 (4.1–18.0) |
| Age at first follow-up (years) | 18.2 (10.9–23.2) |
| Biochemistry at the first follow-up | |
| ALT (U/L) | 21 (14–32) |
| GT (U/L) | 17 (13–34) |
| Total bilirubin (μmol/L) | 10 (8–14) |
| Prealbumin (mg/L) | 210 (170–238) |
| Platelets (E9/L) | 216 (171–282) |
| Time from first follow-up to follow-up (years) | 8.4 (7.4–9.3) |
| Age at follow-up (years) | 25.7 (19.4–32.3) |
ALT – alanine transaminase; AP – alkaline phosphatase; GT – γ-glutamyl transferase; IQR – interquartile range; LT – liver transplantation; PKD – polycystic kidney disease;
*
Diagnostic group metabolic included: Familial hypercholesterolemia (1), hyperoxaluria (1), morbus Wilson (1), OTC-deficiency (1), and tyrosinemia (4).
**
Diagnostic group others included: Budd-Chiari syndrome (1), HUS (1), extrahepatic portal vein thrombosis (1), liver failure of unknown etiology (1), MIRAS mitochondrial recessive ataxia syndrome (1), iron poisoning (2), and sclerosing cholangitis (1).